The Impact of Low-Cost Antibiotic Cotrimoxazole in Patients With COVID-19

The global pandemic Coronavirus Disease 19 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Many patients with life-threatening illness due to COVID-19 die from hypoxic respiratory failure, which appears to be related to a cytokine storm syndrome leading to Acute Respiratory Distress Syndrome (ARDS). While steroids have some demonstrated benefits, supportive care remains the mainstay of treatment. However, in the absence of vaccines and proven treatments, during this current pandemic, we are considering repurposing currently available medications; one of the first is cotrimoxazole (CTX), which was one of the earliest medications for treating and preventing opportunistic infections caused by the human immunodeficiency virus (HIV), among other things. Cotrimoxazole in combination with folic acid is inexpensive, familiar to the public, and generally well tolerated, and treats secondary infections. Low cost and a good safety profile can make it an ideal candidate for the treatment of COVID-19 in a low-resource country like Libya. Here we report our observations with cotrimoxazole added to standard therapy in patients with severe COVID-19. Prospective data were gathered from consecutive newly diagnosed patients who presented to the Msallatah Isolation Center (Corona Center), Msallatah, Libya, between June and September of 2021 with critical COVID-19 on non-invasive ventilation and receiving standard therapy (ST) along with 480 mg oral cotrimoxazole (CTX). The first four days served as a control period during which patients with critical COVID-19 received only standard treatment. After a 4-day control period during which the patients received ST alone, nine patients (mean age ± SEM 40.5 ± 10.5 years, 66.66 percent male) were identified because they received CTX in addition to ST. We found that patients with critical COVID-19 who received CTX in addition to ST experienced significantly better outcomes, such as lower in-hospital mortality (0%), higher blood levels of D-Dimer (3735±579.9 mg/L versus 444.82±182.14 mg/L, p˂0.05), and improvements in respiratory rate (36.42±3.9 mg/L versus 25.6±2.9 mg/L, p˂0.05) and CRP at the fourth day of the experiment (142.12±34.7 mg/L versus 72.4±19.26 mg/L, p˂0.05). These results demonstrate the beneficial effects of using cotrimoxazole in patients with severe COVID-19; it could help to reduce the need for respiratory support for thousands of patients, saving valuable lives and decreasing the burden on the healthcare system in countries with limited resources. The mechanism of action of cotrimoxazole in this situation is not clear; however, these outcomes may be due to the antibiotic activity and/or the anti-cytokine effects of cotrimoxazole. Further trials are needed to test our observations